By Foo Yun Chee and Maggie Fick BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear ...

Novo Nordisk A/S shares rose as surging sales of the blockbuster weight-loss treatment Wegovy reassured investors after rival ...

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

Novo Holdings, Novo Nordisk, and Catalent have all recently reiterated their expectations that the transaction will close ...

Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug ...

Wednesday’s update to the regulator’s drug shortage database is good news for Novo Nordisk, which has struggled to keep up ...

Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk reported its net profit in Q3 hit 27.3 billion Danish ... by December 6 whether to clear Novo Holdings’ acquisition of contract drug manufacturer Catalent. Catalent posted a surprise ...

Novo Holdings, the investment firm that has a controlling interest in Novo Nordisk, agreed to buy Catalent in February to boost the supply of Wegovy. Catalent said the deal is expected to close ...

Novo Holdings, Novo Nordisk and Catalent have all recently reiterated their expectations that the transaction will close towards the end of this year. "We are following all regulatory procedures ...